Hell, not much incentive to go the other way.
1. What is trailing, or contracted, revenue? There is no gray area here. You're either lying or you're not, and lying is committing fraud (as Theranos appears to have done in this case). And no company I've previously worked at has lied about this in my experience.
2. What are the shipping capabilities of your product? Potentially some opportunity for "fluff" depending on how this is answered, but Theranos unambiguously lied here. Again, have never seen plain outright lying in a company I've worked at.
This idea that there is just a ton of lying going on with investors in SV is bullshit. The reason cases like Theranos are pretty extraordinary is they're quite rare.
But honestly, I actually don't think that's much of a big deal. The difference between taking a venous draw and doing a finger stick as not as big of a deal as Theranos made it out to be.
If instead Theranos had a small, portable analysis machine that could work with small volumes of venous blood, and they had a big deal with Walgreens to use that together with things like low, up-front pricing for tests, I think that still would have been a great advance. Note there are startups like Everlywell basically trying to make that vision (cheap, accessible, up-front pricing for medical tests) possible.
Obviously there are huge challenges to designing such an implanted medical device, and it could only ever work for a limited set of assays, but I expect something like that will eventually be possible. We already see diabetics wearing continuous glucose monitors, which gives a preview of how such implanted sensors might operate.